AOP Orphan Launches Lojuxta for Treatment of Homozygous Familial Hypercholesterolaemia to the Austrian Market
The Austrian pharmaceutical company AOP Orphan is launching Lojuxta into the Austrian market. Lojuxta was authorized by the EMA (European Medical Agency) in July 2013. Lojuxta is indicated in adult patients with homozygous familial hypercholesterolaemia (HoFH) as an adjunct to a low-fat diet and other lipid-lowering medications, with or without LDL (low density lipoprotein) apheresis. Genetic confirmation of HoFH should be obtained whenever possible, and other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g., nephrotic syndrome, hypothyroidism) must be excluded.
HoFH: A disease of the LDL receptor with an unmet medical need despite current standard of care
HoFH is a rare genetic disorder inherited from both parents, and characterised by significantly elevated low density lipoprotein cholesterol (LDL-C) levels. Chronic exposure to high LDL-C may lead to premature, severe and progressive atherosclerosis, and may correlate with development of premature cardiovascular disease, such as: acute coronary syndrome, early myocardial infarction, aortic stenosis, ultimately premature and sudden death. As HoFH is a rare disease, it is not possible to conduct randomized controlled cardiovascular outcomes studies in this disease and there are no data on the effect of Lojuxta on cardiovascular outcomes.
HoFH patients have LDL receptors that are either non-functional or are defective in their functioning. Most other drug treatments such as statins work by increasing the number of LDL-receptors and if these are defective or negative, the drugs that work by these mechanisms typically have limited effectiveness in HoFH patients.
In addition, regular lipid apheresis (filtering of the lipids from the blood) is often required and must be repeated every 1 to 2 weeks. The use of lipid lowering drugs with or without apheresis, although effective, do not typically reduce LDL-C levels in HoFH patients to the targets recommended by the European Atherosclerosis Society (EAS) and therefore atherosclerosis may continue to progress.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance